Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Dual Inhibition of PI3K-Delta and Gamma By Duvelisib (IPI-145) Impairs CLL B- and T-Cell Migration, Survival and Proliferation in a Murine Xenograft Model Using Primary Chronic Lymphocytic Leukemia Cells

Shih-Shih Chen, PhD, Steven Ham, Kanti R. Rai, MD, Karen McGovern, PhD, Jeffery L. Kutok, MD PhD, Nicholas Chiorazzi, MD

Blood (2015) 126 (23): 1753.

https://doi.org/10.1182/blood.V126.23.1753.1753

Published: 2015

Journal Articles

Duvelisib (IPI-145) Inhibits Malignant B-Cell Proliferation and Disrupts Signaling from the Tumor Microenvironment through Mechanisms That Are Dependent on PI3K-δ and PI3K-γ

Marisa Peluso, MS, Kerrie Faia, MS, David Winkler, PhD, Nidhi Patel, MS, Erin Brophy, BS, Kerry White, BA, Mark Douglas, MS, Howard M. Stern, MD PhD, Vito Palombella, PhD, Karen McGovern, PhD, Jeffery L. Kutok, MD PhD

Blood (2014) 124 (21): 328.

https://doi.org/10.1182/blood.V124.21.328.328

Published: 2014

Journal Articles

The Potent PI3K-δ,γ Inhibitor, IPI-145, Exhibits Preclinical Activity In Murine and Human T-Cell Acute Lymphoblastic Leukemia

Xiaoyan Huang, MD., MSc, Jennifer Proctor, B.S., Yaling Yang, PhD, Xiuhua Gao, MD, PhD, Weihong Zhang, M.D., Shenjiao Huang, MD, PhD, Paul Changelian, PhD, Jeffery L. Kutok, MD, PhD, Karen McGovern, PhD, M. James You, MD, PhD

Blood (2013) 122 (21): 1438.

https://doi.org/10.1182/blood.V122.21.1438.1438

Published: 2013

Journal Articles

The Potent PI3K-δ,γ Inhibitor IPI-145 Exhibits Differential Activity In Diffuse Large B-Cell Lymphoma (DLBCL) Cell Lines

Veronica Campbell, BS, Ryan Thompson, PhD, Vivian Villegas, MS, Jennifer Proctor, B.S., Karen McGovern, PhD, Jeffery L. Kutok, MD, PhD, Howard M. Stern, M.D., Ph.D.

Blood (2013) 122 (21): 1832.

https://doi.org/10.1182/blood.V122.21.1832.1832

Published: 2013

Journal Articles

Evidence That Activated Hedgehog Signaling Predicts for Poor Clinical Outcome in Acute Myeloid Leukemia

Veronica Campbell, BS, Eleni Tholouli, MD, PhD, M. Travis Quigley, MS, John Keilty, MS, Patrick Kelly, MD, Karen McGovern, PhD, Margaret Read, PhD, Jeffery L. Kutok, MD, PhD, Richard Byers, PhD, MBChB

Blood (2012) 120 (21): 1441.

https://doi.org/10.1182/blood.V120.21.1441.1441

Published: 2012

Journal Articles

Selective Expression of the Immunoregulatory Lectin, Galectin-1, in Precursor B Cell Acute Lymphoblastic Leukemias (ALLs) with MLL Rearrangements

Przemyslaw Juszczynski, MD, PhD, Scott J. Rodig, MD, PhD, Kunihiko Takeyama, MD, PhD, Jing Ouyang, PhD, Jorg Faber, MD, PhD, Scott Armstrong, MD, PhD, Jeffery L. Kutok, MD, PhD, Margaret A. Shipp, MD

Blood (2008) 112 (11): 2539.

https://doi.org/10.1182/blood.V112.11.2539.2539

Published: 2008

Journal Articles

Wilms Tumor 1 Gene (WT1) Isoforms in Leukemia and Lymphoma.

Aihong Li, MD, PhD, Ulla-Britt Westman, BMA, Irina Golovleva, PhD, Jeffery L. Kutok, MD, PhD, Lewis B. Silverman, MD, Stephen E. Sallan, MD, Goran Roos, MD, PhD

Blood (2007) 110 (11): 4265.

https://doi.org/10.1182/blood.V110.11.4265.4265

Published: 2007

Journal Articles

Hodgkin’s Lymphoma Reed Sternberg Cells over Express the T-Cell Inhibitory Carbohydrate-Binding Lectin, Galectin 1: Role of AP-1 and Likely Mechanism of Tumor Immune Escape.

Przemyslaw Juszczynski, MD, PhD, Jing Ouyang, PhD, Jeffery L. Kutok, MD, PhD, Stefano Monti, PhD, Wen Chen, MD, Paola Dal Cin, PhD, Jeremy S. Abramson, MD, Kunihiko Takeyama, MD, PhD, Todd R. Golub, MD, Jon C. Aster, MD, PhD, Gabriel A. Rabinovich, PhD, Margaret A. Shipp, MD

Blood (2006) 108 (11): 469.

https://doi.org/10.1182/blood.V108.11.469.469

Published: 2006

Journal Articles

Heat Shock Protein 90 (HSP90) Is a Rational Therapeutic Target in Diffuse Large B-Cell Lymphoma.

Jeremy S. Abramson, MD, Wen Chen, MD, Hidenobu Takahashi, MD, Przemyslaw Juszczynski, MD, PhD, Jeffery L. Kutok, MD, PhD, Margaret A. Shipp, MD

Blood (2006) 108 (11): 829.

https://doi.org/10.1182/blood.V108.11.829.829

Published: 2006

Journal Articles

FAS Death Domain Deletions and Increased c-FLIPlong Expression Occur in Different Subtypes of Diffuse Large B-Cell Lymphoma.

Hidenobu Takahashi, MD, PhD, Friedrich Feuerhake, MD, Jeffery L. Kutok, MD, PhD, Stefano Monti, PhD, Paola S. Dal Cin, PhD, Donna Neuberg, Sc.D, Jon C. Aster, MD, PhD, Margaret A. Shipp, MD

Blood (2005) 106 (11): 416.

https://doi.org/10.1182/blood.V106.11.416.416

Published: 2005

Journal Articles

Evaluation of CD52 Expression in Hematopoietic Neoplasms by Standard Immunohistochemistry: Implications for the Expanded Use of Alemtuzumab (CAMPATH-1H) in the Treatment of Hematological Malignancies.

Scott J. Rodig, MD, PhD, Jeremy S. Abramson, MD, Geraldine S. Pinkus, MD, Steven P. Treon, MD, PhD, Margaret A. Shipp, MD, Jeffery L. Kutok, MD, PhD

Blood (2005) 106 (11): 3346.

https://doi.org/10.1182/blood.V106.11.3346.3346

Published: 2005

Journal Articles

Complete Absence of the Lineage-Determining Transcription Factor C/EBPα Results in Loss of Myeloid Identity in Bcr/abl Induced Malignancy.

Katharina Wagner, MD, Pu Zhang, MD, Frank Rosenbauer, PhD, Bettina Drescher, PhD, Susumu Kobayashi, MD, Hanna S. Radomska, PhD, Jeffery L. Kutok, MD, Jürgen Krauter, MD, Daniel G. Tenen, MD

Blood (2005) 106 (11): 646.

https://doi.org/10.1182/blood.V106.11.646.646

Published: 2005

Journal Articles

B-Aggressive Lymphoma Gene (BAL) Is a Risk-Related, γIFN-Inducible Gene That Is Expressed in Primary Diffuse Large B-Cell Lymphomas with a Brisk Host Inflammatory Response.

Przemyslaw Juszczynski, MD, PhD, Jeffery L. Kutok, MD, PhD, Ricardo C.T. Aguiar, MD, PhD, Joydeep Mitra, PhD, Margaret A. Shipp, MD

Blood (2004) 104 (11): 2035.

https://doi.org/10.1182/blood.V104.11.2035.2035

Published: 2004

Journal Articles

Molecular Profiling of Diffuse Large B-Cell Lymphoma Identifies Robust Subtypes Including One Characterized by Host Inflammatory Response.

Blood (2004) 104 (11): 25.

https://doi.org/10.1182/blood.V104.11.25.25

Published: 2004

Journal Articles

NFκB Activation in Primary Mediastinal Large B-Cell Lymphoma: Nuclear Localization of c-REL and Coordinate Upregulation of NFκB Target Genes.

Friedrich Feuerhake, MD, Jeffery L. Kutok, MD, PhD, Stefano Monti, PhD, Giorgio Cattoretti, MD, Paul Kurtin, MD, Geraldine S. Pinkus, MD, Laurence de Leval, MD, Nancy L. Harris, MD, Kerry J. Savage, MD, Thomas M. Habermann, MD, Riccardo Dalla-Favera, MD, Todd R. Golub, MD, Jon C. Aster, MD, PhD, Margaret A. Shipp, MD, PhD

Blood (2004) 104 (11): 243.

https://doi.org/10.1182/blood.V104.11.243.243

Published: 2004

Journal Articles

Evidence for Ineffective Erythropoiesis in Patients with Severe Sickle Cell Anemia.

Catherine J. Wu, MD, Lakshamanan Krishnamurti, MD, Jeffery L. Kutok, MD, PhD, Melinda Biernacki, Shelby A. Rogers, Joseph H. Antin, MD, Jerome Ritz, MD

Blood (2004) 104 (11): 105.

https://doi.org/10.1182/blood.V104.11.105.105

Published: 2004

NARROW

Dual Inhibition of PI3K-Delta and Gamma By Duvelisib (IPI-145) Impairs CLL B- and T-Cell Migration, Survival and Proliferation in a Murine Xenograft Model Using Primary Chronic Lymphocytic Leukemia Cells

Duvelisib (IPI-145) Inhibits Malignant B-Cell Proliferation and Disrupts Signaling from the Tumor Microenvironment through Mechanisms That Are Dependent on PI3K-δ and PI3K-γ

The Potent PI3K-δ,γ Inhibitor, IPI-145, Exhibits Preclinical Activity In Murine and Human T-Cell Acute Lymphoblastic Leukemia

The Potent PI3K-δ,γ Inhibitor IPI-145 Exhibits Differential Activity In Diffuse Large B-Cell Lymphoma (DLBCL) Cell Lines

Evidence That Activated Hedgehog Signaling Predicts for Poor Clinical Outcome in Acute Myeloid Leukemia

Selective Expression of the Immunoregulatory Lectin, Galectin-1, in Precursor B Cell Acute Lymphoblastic Leukemias (ALLs) with MLL Rearrangements

Wilms Tumor 1 Gene (WT1) Isoforms in Leukemia and Lymphoma.

Hodgkin’s Lymphoma Reed Sternberg Cells over Express the T-Cell Inhibitory Carbohydrate-Binding Lectin, Galectin 1: Role of AP-1 and Likely Mechanism of Tumor Immune Escape.

Heat Shock Protein 90 (HSP90) Is a Rational Therapeutic Target in Diffuse Large B-Cell Lymphoma.

FAS Death Domain Deletions and Increased c-FLIPlong Expression Occur in Different Subtypes of Diffuse Large B-Cell Lymphoma.

Evaluation of CD52 Expression in Hematopoietic Neoplasms by Standard Immunohistochemistry: Implications for the Expanded Use of Alemtuzumab (CAMPATH-1H) in the Treatment of Hematological Malignancies.

Complete Absence of the Lineage-Determining Transcription Factor C/EBPα Results in Loss of Myeloid Identity in Bcr/abl Induced Malignancy.

B-Aggressive Lymphoma Gene (BAL) Is a Risk-Related, γIFN-Inducible Gene That Is Expressed in Primary Diffuse Large B-Cell Lymphomas with a Brisk Host Inflammatory Response.

Molecular Profiling of Diffuse Large B-Cell Lymphoma Identifies Robust Subtypes Including One Characterized by Host Inflammatory Response.

NFκB Activation in Primary Mediastinal Large B-Cell Lymphoma: Nuclear Localization of c-REL and Coordinate Upregulation of NFκB Target Genes.

Evidence for Ineffective Erythropoiesis in Patients with Severe Sickle Cell Anemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only